CClinicalTrials.gg
RecruitingNCT06163092Updated Mar 20, 2025

Chronic Endometritis and Benefits of Antibiotics in Women With Recurrent Miscarriage

An observational study in Recurrent Miscarriage, sponsored by Chinese University of Hong Kong. Recruiting at 1 site in Hong Kong. Open to female participants aged 20 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-03-20.

Sponsored by Chinese University of Hong Kong · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
175
Ages
20 Years to 45 Years
Sex
Female
01

Study summary

The aim of the study is to estimate the incidence of CE, evaluate the endometrial microorganism of CE, and investigate the therapeutic benefits of antibiotics for women with unexplained recurrent miscarriage and CE.

Read the detailed description

Eligible women, based on the inclusion and exclusion criteria, will be recruited from the miscarriage clinic in the Prince of Wales Hospital. Endometrial sampling (ES) will alternatively be conducted during mid-luteal phase. In natural cycles, all the subjects will have a daily urine test from day 9 of the menstrual cycle to identify the Luteinizing Hormone (LH) surge. The ES will be obtained precisely 7 days after LH surge. Endometrial samples will be obtained using a Pipelle sampler as an outpatient procedure. The endometrium will be divided into three aliquots. One will be fixed in 4% formalin for 24 hours, routinely processed and embedded in paraffin wax. One will be investigated by microbial culture for infectious agents and one will be sequenced to reveal the endometrial microbiota.

CE will be diagnosed either by the presence of plasma cells and changes in endometrial stromal cells identified using HE and IHC, or by the finding of infectious agents using microbial culture. The selection of antibiotics will be based on the type of infectious agents or empirical, doxycycline 100mg BD po. for 14 days, for women with negative microbial culture. Endometrial biopsy will be repeated at the same time point after antibiotic treatment for women with CE. For persistent subjects with negative culturing, ciprofloxacin 500mg, BD po., and metronidazole 400mg TDS po. for 14 days will be used. The treatment will be repeated for three courses at maximum for women with persistent CE according to their willingness.

02

Conditions studied

  • Recurrent Miscarriage

Keywords

  • chronic endometritis
  • antibiotics
  • unexplained recurrent miscarriage women
03

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects will be identified and recruited from the miscarriage clinic by clinicians and research assistants and research nurse.

Inclusion criteria

  • Women with a history of 2 or more consecutive miscarriages before 24 weeks of gestation
  • Women aged 20-45 years old

Exclusion criteria

Exclusion Criteria:

  • Uncorrected uterine anomalies, such as the septate or bicornuate uterus, fibroids (submucous/intramural)
  • Untreated hydrosalpinx
  • Antiphospholipid syndrome
  • Known clinical autoimmune disease
  • Undergoing immunotherapy
  • Abnormal thyroid function
  • Abnormal karyotyping of couples
  • Known immunodeficiency pathologies such as diabetes or HIV
  • Currently taking other antibiotics or other trial medications or TCM;
  • Currently or previously involved in other clinical trials with medication intake;
  • Those with active pelvic inflammatory disease or suspicion of infection etc.
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
175 participants (estimated)
Patient registry
No

Groups and cohorts

  • Observational study

    Women with recurrent miscarriage would be invited to do endometrial sampling (ES) procedure. The ES will be conducted precisely 7 days after LH surge. It will be obtained using a Pipelle sampler as an outpatient procedure.

05

What researchers measure

Primary outcomes

  1. the incidence of chronic endometritis in local women with unexplained recurrent miscarriage

    the incidence of chronic endometritis in local women with unexplained recurrent miscarriage

    Time frame: 31 January 2027

Secondary outcomes

  1. Investigate the spectrum of endometrial microorganisms associated with chronic endometritis in this population

    Investigate the spectrum of endometrial microorganisms associated with chronic endometritis in this population

    Time frame: 31 January 2027

  2. Assess the clinical pregnancy outcomes between cured CE group and non-CE group

    Assess the clinical pregnancy outcomes in both cured CE group and non-CE group

    Time frame: 31 January 2027

06

Study locations

1 of 1 sites recruiting
  • The Chinese University of Hong Kong
    Hong Kong, Hong Kong
    • PUI WAH JACQUELINE CHUNG, MBBS · Contact · jacquelinechung@cuhk.edu.hk · +852 35051537
    • Stacey Wong, Bsc · Contact · staceywong@cuhk.edu.hk · +852 35051764
    • PUI WAH JACQUELINE CHUNG, MBBS · Principal investigator
    • TAO ZHANG, MBBS · Sub investigator
    • JING XI JOSHUA LI, MBBS · Sub investigator
    • WAI YIN NG, MBBS · Sub investigator
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT06163092
Lead sponsor
Chinese University of Hong Kong
Responsible party
Chung Pui Wah Jacqueline (Associate Professor, Chinese University of Hong Kong) — Principal investigator
First posted
Dec 8, 2023
Start date
Apr 1, 2024
Primary completion
Jan 31, 2026 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Mar 20, 2025

Study contacts

Stacey Wong, BSc
Contact
staceywong@cuhk.edu.hk
35051764
Jacqueline Pui Wah Chung, MBBS
Contact
jacquelinechung@cuhk.edu.hk
35051764
Jacqueline Pui Wah Chung, MBBS
principal investigator · Chinese University of Hong Kong

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion